Baker SP, Whitfield RA, O'Neill B Geographic variations in mortality from motor vehicle crashes. N Engl J Med. 1987 May 28;316(22):1384-7. doi: 10.1056/NEJM198705283162206.
Cannon JW Hemorrhagic Shock. N Engl J Med. 2018 Jan 25;378(4):370-379. doi: 10.1056/NEJMra1705649. No abstract available.
Cohen MJ, Christie SA New understandings of post injury coagulation and resuscitation. Int J Surg. 2016 Sep;33(Pt B):242-245. doi: 10.1016/j.ijsu.2016.05.037. Epub 2016 May 19.
Davenport RA, Brohi K Coagulopathy in trauma patients: importance of thrombocyte function? Curr Opin Anaesthesiol. 2009 Apr;22(2):261-6. doi: 10.1097/ACO.0b013e328325a6d9.
Kauvar DS, Lefering R, Wade CE Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J Trauma. 2006 Jun;60(6 Suppl):S3-11. doi: 10.1097/01.ta.0000199961.02677.19.
Kornblith LZ, Kutcher ME, Redick BJ, Calfee CS, Vilardi RF, Cohen MJ Fibrinogen and platelet contributions to clot formation: implications for trauma resuscitation and thromboprophylaxis. J Trauma Acute Care Surg. 2014 Feb;76(2):255-6; discussion 262-3. doi: 10.1097/TA.0000000000000108.
Kozar RA, Pati S Syndecan-1 restitution by plasma after hemorrhagic shock. J Trauma Acute Care Surg. 2015 Jun;78(6 Suppl 1):S83-6. doi: 10.1097/TA.0000000000000631. No abstract available.
Li R, Elmongy H, Sims C, Diamond SL Ex vivo recapitulation of trauma-induced coagulopathy and preliminary assessment of trauma patient platelet function under flow using microfluidic technology. J Trauma Acute Care Surg. 2016 Mar;80(3):440-9. doi: 10.1097/TA.0000000000000915.
Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001 Sep 25;104(13):1533-7. doi: 10.1161/hc3801.095588.
Murray CJ, Lopez AD Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997 May 3;349(9061):1269-76. doi: 10.1016/S0140-6736(96)07493-4.
Nachman RL, Rafii S Platelets, petechiae, and preservation of the vascular wall. N Engl J Med. 2008 Sep 18;359(12):1261-70. doi: 10.1056/NEJMra0800887. No abstract available.
Rondina MT, Grissom CK, Men S, Harris ES, Schwertz H, Zimmerman GA, Weyrich AS Whole blood flow cytometry measurements of in vivo platelet activation in critically-Ill patients are influenced by variability in blood sampling techniques. Thromb Res. 2012 Jun;129(6):729-35. doi: 10.1016/j.thromres.2011.11.031. Epub 2011 Dec 16.
Sauaia A, Moore FA, Moore EE, Lezotte DC Early risk factors for postinjury multiple organ failure. World J Surg. 1996 May;20(4):392-400. doi: 10.1007/s002689900062.
Scope A, Farkash U, Lynn M, Abargel A, Eldad A Mortality epidemiology in low-intensity warfare: Israel Defense Forces' experience. Injury. 2001 Jan;32(1):1-3. doi: 10.1016/s0020-1383(00)00101-7.
Ware LB, Fang X, Matthay MA Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003 Sep;285(3):L514-21. doi: 10.1152/ajplung.00442.2002. Epub 2003 May 16.
White NJ, Ward KR, Pati S, Strandenes G, Cap AP Hemorrhagic blood failure: Oxygen debt, coagulopathy, and endothelial damage. J Trauma Acute Care Surg. 2017 Jun;82(6S Suppl 1):S41-S49. doi: 10.1097/TA.0000000000001436.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.